Modality
ADC
MOA
ALKi
Target
KIF18A
Pathway
Apoptosis
Cholangiocarcinoma
Development Pipeline
Preclinical
May 2024
→ Sep 2027
PreclinicalCurrent
NCT06449016
1,124 pts·Cholangiocarcinoma
2024-05→2027-09·Recruiting
NCT08884888
517 pts·Cholangiocarcinoma
2025-10→2027-09·Completed
1,641 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-111.4y awayInterim· Cholangiocarcinoma
2027-09-231.5y awayInterim· Cholangiocarcinoma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Recruit…
Preclinical
Complet…
Catalysts
Interim
2027-09-11 · 1.4y away
Cholangiocarcinoma
Interim
2027-09-23 · 1.5y away
Cholangiocarcinoma
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06449016 | Preclinical | Cholangiocarcinoma | Recruiting | 1124 | PASI75 |
| NCT08884888 | Preclinical | Cholangiocarcinoma | Completed | 517 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |